NEW YORK, June 5 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. (AAH: ASX). The full 56-page report can be found at http://www.crystalra.com .
Arana Therapeutics Ltd. ("Arana" or "the Company") is a biotechnology company developing next-generation antibody therapeutics to treat inflammatory diseases and cancer. Arana's business is divided into two sectors: (1) protein engineering technologies; and (2) therapeutics development. The Company's technology platform includes its Superhumanisation(TM), Synhumanisation(R), and EvoGene(TM) proprietary processes. Application of these technologies can transform lead proteins, including antibodies, into safe, potent therapeutic candidates. The resulting products may be less immunogenic (less likely to cause side effects) yet retain the crucial binding properties of the starting antibody.
At present, the Company licenses its protein engineering platform to CSL Ltd. (CSL-ASX), GlaxoSmithKline plc (GSK-NYSE), Aveo Pharmaceuticals, Inc., and Vegenics Ltd. Additionally, Arana can use its technologies to decrease the timeline and minimize the financial risks of its therapeutic antibody development. The Company does this by further enhancing already validated targets that would otherwise be excluded from development due to existing competitor patents.
Arana's product pipeline consists of eight candidates targeting
inflammatory diseases as well as bone, lung, and colorectal cancer,
melanoma, leukemia, and solid tumors. ART621, the Company's most advanced
candidate, is a Tumor Necrosis Factor alpha (TNF alpha)-blocker for
rheumatoid arthritis (RA), psoriasis, and Crohn's disease. In March 2008,
the Company commenced Phase II clinical trials of ART621 in psoriasis
patients. Within Arana's Cancer Franchise, the lead product candidate is
ART010, an e
|SOURCE Crystal Research Associates, LLC|
Copyright©2008 PR Newswire.
All rights reserved